SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-201161
Filing Date
2023-08-02
Accepted
2023-08-02 07:37:53
Documents
14
Period of Report
2023-08-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d542880d8k.htm   iXBRL 8-K 25199
2 EX-99.1 d542880dex991.htm EX-99.1 112800
6 GRAPHIC g542880g0802050507812.jpg GRAPHIC 3433
  Complete submission text file 0001193125-23-201161.txt   283431

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20230802.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20230802_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20230802_pre.xml EX-101.PRE 11258
8 EXTRACTED XBRL INSTANCE DOCUMENT d542880d8k_htm.xml XML 3342
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 231133741
SIC: 2834 Pharmaceutical Preparations